SEC Form 4 · accession 0001209191-18-046026
Viridian Therapeutics, Inc.\DE · VRDN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jason A. Leverone
Officer — CFO, Treasurer & Secretary
Period of report
Aug 7, 2018
Accepted (ET)
Aug 9, 2018 · 4:18 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001590750
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 7, 2018 | M | 29,530 | $0.57 | A | 30,737 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $0.57 | Aug 7, 2018 | M | 29,530 | D | — | Dec 9, 2018 | Common Stock | 29,530 | 0 | D |
Explanation of responses
- F1The option is fully vested and exercisable. The option expires ten years after the date of grant.